Yeah. For balance, there was also this......
Wednesday November 1, 8:00 am Eastern Time
Press Release
SOURCE: Packard BioScience Company
Packard BioScience Delivers Key Biochip Printing
Devices to Motorola
MERIDEN, Conn. and NORTHBROOK, Ill., Nov. 1 /PRNewswire/ -- Motorola, Inc. (NYSE: MOT - news) and Packard
BioScience Company (Nasdaq: PBSC - news) announced today that Packard has successfully delivered factory-tested
biochip production devices to Motorola's Life Sciences. In 1999, Motorola and Packard signed a collaboration and
non-exclusive licensing agreement granting Motorola early access rights to Packard's patented inkjet printing technology for the
production of biochips and microarrays. Under this agreement, both companies agreed to collaborate on the development of
industrial-scale biochip production equipment. Terms of the agreement were not disclosed.
``Packard's production technology fits extremely well with the development of our three-dimensional bioarray platform,'' said
Nicholas Naclerio, vice president and general manager of Motorola's BioChip Systems business. ``Providing quality products
that are consistent in their content and performance are some of the key advantages of our system. This technology
collaboration helps ensure that we are setting a new quality standard for bioarray manufacturing.'' Alastair Malcolm, vice
president of operations for Motorola BioChip Systems added: ``This unique high-throughput piezo dispensing technology is a
key part of our ability to produce large quantities of high density arrays in the upcoming year. The combined benefit of accuracy
and speed enables us to achieve both our volume and quality requirements.''
Emery G. Olcott, president and CEO of Packard BioScience said, ``We are pleased to have a very quality-oriented company
such as Motorola as our first strategic partner to commercialize this groundbreaking technology.'' In addition he stated, ``The
achievement of this delivery milestone validates the world-class value of our biochip production tools. The business
opportunities for this technology are vast, and our commercialization plan is based on a two-pronged approach: first, to
propagate the technology throughout various industries by licensing agreements with strategic partners and second, to put it into
full commercial production for the distribution of value-added products through our own global sales organization.''
About Packard BioScience
Packard BioScience Company is a leading global developer, manufacturer and marketer of instruments and related
consumables and services for use in the life sciences research and environmental industries. The Company is primarily focused
on the rapidly growing areas of drug discovery, genomics and biochip analysis and is continuing to develop integrated platforms
based on a wide range of technologies and instrumentation. These platforms are designed to support the industrialization of drug
discovery by bringing the benefits of miniaturization, automation and ultra-high throughput analysis to these areas. Packard's
experience in working in more than 60 countries with market leading customers has allowed the Company to establish a
worldwide leadership position in many of its primary product categories, with well-recognized brand names and a reputation for
high quality, reliable instruments.
About Motorola Inc.
Motorola, Inc. (NYSE: MOT - news) is a global leader in providing integrated communications solutions and embedded
electronic solutions. Sales in 1999 were $33.1 billion. For more information, visit Motorola at motorola.com.
Motorola BioChip Systems was established in 1998 to develop products which enable the delivery of better healthcare through
the understanding and practical application of genomics. The business unit is currently developing a family of biochip products
and services for research and diagnostic applications. The products under development at Motorola BioChip Systems will
enable scientists and healthcare professionals to quickly and accurately analyze the DNA, RNA and proteins in living cells. In
the future, the outcomes from this work will lead to the delivery of faster and more individualized healthcare.
Motorola and the Motorola logo are registered trademarks of Motorola Inc.
Certain statements contained herein are ``forward-looking'' statements which involve a high degree of risk and uncertainty,
including, without limitation, the prospective statements regarding the expected expansion of biochip applications and the
Company's ability to capitalize on such expansion, and may be identified by the use of forward-looking words or phrases such
as ``expected,'' ``expecting'' or ``anticipated.'' Many factors could cause actual results to differ materially from these statements
including, without limitation, loss of market share from competition, the ability to successfully introduce new products and
platforms, market acceptance of new products and platforms, the Company's ability to protect its intellectual property, not
infringing on the intellectual property rights of others, changes in the markets the Company serves and economic issues such as
interest rate and foreign exchange fluctuations. These and other risk factors are discussed in detail in the Company's filings with
the Securities and Exchange Commission.
Contact: Mike Zebarth of Packard BioScience, 203-639-2340, mzebarth@packardbioscience.com; or John Capodanno, ext.
246, investors, j.capodanno@noonanrusso.com, or Hala Bashir, ext. 356, media, h.bashir@noonanrusso.com, both
Noonan-Russo Communications, Inc., 212-696-4455, for Packard BioScience Company; or Anne Stuessy of Motorola Inc.,
847-538-6192, anne.stuessy@motorola.com
SOURCE: Packard BioScience Company |
